Loading...

Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside

The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstroms macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLC?2 can also mediate resi...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Wu, Jingjing, Zhang, Mingzhi, Liu, Delong
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2016
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5351700/
https://ncbi.nlm.nih.gov/pubmed/27776353
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12786
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!